Any content you receive is for information purposes only. Always conduct your own research. |
*Sponsored |
Daily Edge Report Puts (Nasdaq: ALZN) On The Top of Tomorrow's Watchlist—Thursday, March 26, 2026 |
Don't miss the next breakout — get real-time alerts sent straight to your phone! |
We'll Have Full Coverage On This One Early |
Pull Up (ALZN) Before Tomorrow Morning… |
March 25th, 2026
New Coverage Announced: See Why (ALZN) Just Hit Our Early Morning Watchlist. |
Dear Readers,
For over 50 years, one of medicine's most recognized compounds has continued to stand the test of time. |
Few treatments carry the same kind of proven history and consistent performance. |
The catch? Its impact may have been limited by how it's been delivered—until now. |
A new method is starting to make waves for tackling that core issue head-on, and it's getting plenty of attention from researchers, doctors, and biotech watchers alike. |
All eyes are on key data expected in early 2026, as many are eager to see whether this next step can unlock more of the compound's potential. |
That growing interest helps explain why Alzamend Neuro, Inc. (Nasdaq: ALZN) landed on our radar and is topping our watchlist this Friday. |
A quick note on this profile: according to Yahoo Finance, ALZN has fewer than 4Mn shares available to the public. When companies have a small float, the potential for heightened volatility could be significant. |
We've already seen signs of that. Over the past month and a half, ALZN climbed about 46%, rising from roughly $1.61 on February 13th to $2.35+ on March 16th. |
And there's more buzz building. Analyst Edward Woo, CFA, at Ascendiant Capital Markets, recently set a price target of $28 for ALZN. That's more than a 1,400% potential upside compared to ALZN's opening valuation on Wednesday. |
|
ALZN is developing a re-engineered version of lithium designed to reach the brain more effectively while limiting toxic side effects elsewhere in the body. |
As the company approaches this important milestone, the biotech world is watching for results that could reshape the standard of care for a vast number of patients living with Alzheimer's and psychiatric disorders. |
ALZN's Mission To Modernize Neuroscience |
Alzamend Neuro, Inc. (Nasdaq: ALZN) is a clinical-stage biopharmaceutical company dedicated to developing novel products that address the massive unmet needs in the treatment of Alzheimer's disease, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). |
Unlike many biotechnology firms that chase entirely unproven biological targets, ALZN is utilizing a "known quantity" approach by taking lithium—a mineral with decades of proven efficacy—and optimizing its delivery through cutting-edge chemical engineering. |
The company's strategy is built on the reality that while lithium is one of the most effective tools in a psychiatrist's arsenal, its "old-school" formulations are fraught with complications. |
Current lithium salts, like lithium carbonate, often struggle to cross the blood-brain barrier efficiently. This forces doctors to prescribe higher doses, which leads to high concentrations in the bloodstream. |
These systemic levels can be detrimental to the kidneys and thyroid, requiring patients to undergo lifelong, invasive blood monitoring. |
ALZN intends to break this cycle of toxicity with its primary candidate, AL001. |
ALZN Pipeline Overview |
|
Alzamend Neuro, Inc. (Nasdaq: ALZN)'s research program currently includes two primary therapeutic candidates focused on neurological and psychiatric conditions. |
ALZN's lead program, AL001, is a patented ionic cocrystal formulation of lithium designed to improve how lithium reaches the brain and is being studied for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. |
In addition to AL001, ALZN is also developing ALZN002, a cell-based immunotherapy approach designed to stimulate the immune system to help combat Alzheimer's disease by targeting beta-amyloid buildup in the brain. |
AL001: The Ionic Cocrystal Breakthrough |
At the heart of the Alzamend Neuro story is AL001, a patented ionic cocrystal of lithium, salicylate, and L-proline. |
This is not just a new pill; it is a sophisticated delivery vehicle designed to improve the pharmacokinetics of lithium. |
By combining these specific compounds, the AL001 formulation is designed to improve how lithium reaches the brain. |
In preclinical mouse studies, this technology demonstrated a remarkable ability to achieve higher brain uptake while maintaining lower levels in the blood compared to standard lithium carbonate. |
This "brain-first" approach is particularly vital for the company's target indications. |
For an Alzheimer's patient, the goal is neuroprotection and the reduction of cognitive decline; for a patient with bipolar disorder, it is mood stabilization. Both require the dr-ug to reach the central nervous system.
By potentially achieving therapeutic brain exposure with a lower systemic dose, ALZN aims to offer the benefits of lithium without the constant threat of organ damage. |
The "Lithium In Brain" Phase II Potential Catalyst |
|
The most anticipated milestone for Alzamend Neuro is the upcoming topline data from its Phase II "Lithium in Brain" study, conducted in partnership with Massachusetts General Hospital. |
This is not a standard clinical trial; it utilizes state-of-the-art 7Li MRI technology equipped with a custom-built head coil. This advanced imaging allows researchers to literally map lithium inside the human brain in real-time. |
The study compares AL001 head-to-head with a marketed lithium carbonate product in healthy subjects. The goal is to determine whether ALZN's formulation can deliver more lithium to specific brain structures while maintaining safer blood levels compared with lithium carbonate. |
The clinical portion of this trial was completed in late 2025, and the topline data is expected in the first quarter of 2026. This data will provide a foundational step toward demonstrating proof‑of‑concept for the AL001 platform. |
The company is aiming for the topline human data to mirror the preclinical proof‑of‑concept results in mice, which demonstrated reduced systemic exposure and enhanced brain penetration in target areas. |
Removing Commercial Barriers: The TDM Factor |
One of the greatest barriers to lithium adoption is therapeutic dr-ug monitoring (TDM). |
Because the line between a therapeutic dose and a toxic dose is so thin with traditional lithium, patients must have their blood drawn frequently. This is a massive inconvenience for patients and a significant liability for physicians. |
ALZN believes that because AL001 can maintain safer systemic levels, it may eliminate the need for TDM. |
If the FDA eventually approves a lithium treatment that does not require constant blood tests, the market potential could expand exponentially. It would allow lithium to be prescribed more freely in primary care settings and for fragile populations, such as the elderly, who often have compromised kidney function and cannot risk standard lithium therapy. |
Market Potential And Strategic Positioning |
The commercial landscape for AL001 is broad. Alzheimer's disease alone remains one of the largest unmet-need markets in global medicine, where even therapies with modest cognitive benefits can generate significant annual sales. |
By targeting four major indications—Alzheimer's, Bipolar, MDD, and PTSD—Alzamend Neuro is positioning AL001 as a platform-level asset.
The company is led by an experienced management team and guided by a Scientific Advisory Board that includes world-renowned experts in neuroscience. |
This leadership has been instrumental in securing partnerships with top-tier institutions like Massachusetts General Hospital and ensuring that the clinical program is designed to meet the highest regulatory standards. |
|
Grab Sources And More Here: ALZN Website. ALZN Presentation. |
----- |
7 Key Potential Catalysts Pin (ALZN) To The Top Of Thursday's Watchlist
#1. Low Float: With fewer than 4Mn shares available to the public according to Yahoo Finance, ALZN's small float could have the potential to witness big moves if demand begins to shift. |
#2. Recent Momentum: Over the past month and a half, ALZN made an approximate 46% move, from around $1.61 on February 13th to $2.35+ on March 16th. |
#3. Analyst Target: Ascendiant Capital Market analyst Edward Woo, CFA, recently highlighted a $28 target on ALZN, which suggests over 1,400% upside potential from its open on Wednesday. |
#4. Upcoming Data: Topline results from the Phase II "Lithium in Brain" study involving ALZN are expected in early 2026, creating a widely watched scientific milestone for the company. |
#5. Advanced Imaging: Researchers evaluating ALZN are using specialized 7Li MRI mapping technology that can measure lithium distribution inside the human brain in real time. |
#6. Novel Formulation: The patented ionic cocrystal used by ALZN combines lithium, salicylate, and L-proline in a formulation designed to improve how lithium reaches the brain. |
#7. Large Indications: The development program surrounding ALZN is focused on Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD—four major neurological and psychiatric conditions with substantial global patient populations. |
----- |
(ALZN) will be front and center for us tomorrow morning—Thursday, March 26, 2026. |
Go ahead and pull up (ALZN) before you wrap up for the evening. |
Also, be on the lookout for our morning update—it could land ahead of schedule. |
Sincerely, |
Joel Locke |
Senior Editor |
The Daily Edge Report |
DailyEdgeReport.com ("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. |
Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 03/25/2026 and ending on 03/26/2026 to publicly disseminate information about (ALZN:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC fifteen thousand USD ("Funds"). These Funds were part of the one hundred fifty thousand USD funds that TD Media LLC received from Alzamend Neuro Inc., the issuer of (ALZN:US). |
Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (ALZN:US). |
Please see important disclosure information here: https://dailyedgereport.com/disclosure/alzn-bPVFe/#details |
No comments:
Post a Comment